



OPEN ACCESS

ORIGINAL RESEARCH

USF1 defect drives p53 degradation during *Helicobacter pylori* infection and accelerates gastric carcinogenesis

Lionel Costa,^{1,2,3} Sébastien Corre,⁴ Valérie Michel,¹ Krysten Le Luel,^{1,3} Julien Fernandes,^{1,5} Jason Ziveri,^{1,6} Gregory Jouvion,⁷ Anne Danckaert,⁵ Nicolas Mouchet,⁴ David Da Silva Barreira,^{1,8} Javier Torres,⁹ Margarita Camorlinga,⁹ Mario Milco D'Elis,¹⁰ Laurence Fiette,^{7,11} Hilde De Reuse,¹ Marie-Dominique Galibert,^{4,12} Eliette Touati ¹

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/gutjnl-2019-318640>).

For numbered affiliations see end of article.

Correspondence to

Dr Eliette Touati, Unit of Helicobacter Pathogenesis, Department of Microbiology, Institut Pasteur, Paris 75015, France; etouati@pasteur.fr

M-DG and ET are joint senior authors.

Received 5 March 2019
Revised 24 October 2019
Accepted 24 November 2019
Published Online First
10 December 2019

ABSTRACT

Objective *Helicobacter pylori* (*Hp*) is a major risk factor for gastric cancer (GC). *Hp* promotes DNA damage and proteasomal degradation of p53, the guardian of genome stability. *Hp* reduces the expression of the transcription factor USF1 shown to stabilise p53 in response to genotoxic stress. We investigated whether *Hp*-mediated USF1 deregulation impacts p53-response and consequently genetic instability. We also explored in vivo the role of USF1 in gastric carcinogenesis.

Design Human gastric epithelial cell lines were infected with *Hp*7.13, exposed or not to a DNA-damaging agent camptothecin (CPT), to mimic a genetic instability context. We quantified the expression of *USF1*, *p53* and their target genes, we determined their subcellular localisation by immunofluorescence and examined USF1/p53 interaction. *Usf1*^{-/-} and INS-GAS mice were used to strengthen the findings in vivo and patient data examined for clinical relevance.

Results In vivo we revealed the dominant role of USF1 in protecting gastric cells against *Hp*-induced carcinogenesis and its impact on p53 levels. In vitro, *Hp* delocalises USF1 into foci close to cell membranes. *Hp* prevents USF1/p53 nuclear built up and relocates these complexes in the cytoplasm, thereby impairing their transcriptional function. *Hp* also inhibits CPT-induced USF1/p53 nuclear complexes, exacerbating CPT-dependent DNA damaging effects.

Conclusion Our data reveal that the depletion of USF1 and its de-localisation in the vicinity of cell membranes are essential events associated to the genotoxic activity of *Hp* infection, thus promoting gastric carcinogenesis. These findings are also of clinical relevance, supporting USF1 expression as a potential marker of GC susceptibility.

INTRODUCTION

Helicobacter pylori (*Hp*) is responsible for about 90% of gastric cancer (GC) cases worldwide,^{1–3} which represents the highest frequency of infectious agents-associated cancer (5.5%).⁴ Importantly, the detection of preneoplasia⁵ and *Hp* eradication during early stages of the precancerous cascade can prevent GC development.^{6,7} GC is an inflammation-driven disease

Significance of this study

What is already known on this subject?

- *Helicobacter pylori* (*Hp*) is a major risk factor for gastric cancer (GC).
- *Hp* promotes p53 proteasomal degradation and inhibits USF1 expression.
- In response to DNA damaging agents, USF1 binds to p53 and inhibits its degradation.

What are the new findings?

- Low USF1 and p53 levels are associated with low overall survival in human GC patients.
- Loss of USF1 accelerates gastric carcinogenesis.
- Only *Hp* and not genotoxic chemicals, leads to USF1 accumulation as structure-like foci at the periphery of the cells.
- *Hp* inhibits USF1/p53 nuclear interaction and impairs DNA repair function.

How might it impact on clinical practice in the foreseeable future?

- Depletion of USF1 in gastric tumorous tissue can be an indicator of a poor prognosis and may become a new biomarker to identify subgroup of patients with higher risk of GC.
- Identification of drugs able to inhibit cytoplasmic accumulation of USF1 or its nuclear depletion can allow future development of targeted therapies to improve GC treatment.

resulting from the complex interplay between bacterial, host and environmental factors.⁸ *Hp*-induced chronic inflammation contributes to neoplastic transformation, via dysregulation of signalling pathways, cell proliferation and genetic instability.⁹ We previously reported that *Hp* induces mutations in chronically infected mice.^{10–12} *Hp* also causes DNA double strand breaks^{13 14} and impairs DNA repair pathways, favouring overall mutation load.^{12 15 16} Importantly, *Hp* promotes the accumulation of mutations in the tumour suppressor gene *TP53*,¹⁷ which have been reported in 50% of gastric tumours.^{17 18} In response to genotoxic stress, p53 activates signalling pathways



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Costa L, Corre S, Michel V, et al. *Gut* 2020;**69**:1582–1591.

leading to temporary cell cycle arrest allowing DNA damage and cellular repair.¹⁹ Its inactivation promotes genome instability, a hallmark of cancer.²⁰ The inhibition of p53 has thus emerged as a strategy of bacterial pathogens to modulate host cellular functions,²¹ as for *Hp* which promotes p53 proteasomal degradation.^{22–24} Together, this results in accumulation of oncogenic changes in infected cells.

Finally, *Hp* induces aberrant DNA methylation that downregulates the expression of genes related to signal transduction pathways and tumour suppression.^{25–27} We reported that *Hp* induces DNA hypermethylation in the promoter region of the upstream stimulating transcription factors genes, *USF1* and *USF2*, inhibiting their expression in infected mice concomitantly to the development of gastric preneoplasia.²⁸ *USF1* and *USF2* are b-HLH-LZ transcription factors ubiquitously expressed. They regulate stress and immune responses, cell cycle control, inflammation and genome stability related genes.²⁹ They may thus act as tumour suppressors.^{30–31} We previously showed that under ultra-violet (UV) stress, *USF1* up-regulates *CSA* and *HR23A* genes expression, two actors of the transcription-coupled and global genome nucleotide excision repair pathway (TC-NER and GG-NER), respectively.³² *USF1* also binds p53 in response to UV-induced DNA damage, preventing the E3-ubiquitin ligase HDM2-p53 interaction. This results in p53 stabilisation and transient cell cycle arrest.³³ How *USF1* modulates p53 levels in response to *Hp* and the consequences on the infection-associated genotoxicity have never been addressed.

In the present study, we investigate the role of both *USF1* and p53 transcription factors in gastric carcinogenesis and asked whether *USF1* deregulation during *Hp* infection could impact the p53-response and increase genetic instabilities. Using a mouse model, we showed that the absence of *USF1* has strong implications in the oncogenic properties of *Hp*, triggering the severity of gastric lesions. In line with these data, low expression levels of both *USF1* and *TP53* and consequently deregulation of their target genes, are observed in a significant number of GC patients, associated with a worse prognosis. Our findings show that *USF1* is a key player in the complex regulatory network linking *Hp* infection to gastric carcinogenesis and pave the way to a better understanding of the mechanisms at the origin of pathogen-induced cancer.

RESULTS

Low *USF1* and p53 levels are associated with a worse prognosis in GC patients

Using The Cancer Genome Atlas (TCGA) data sets, GC patients (STAD) are distinguished according to their overall survival (top 25% low vs top 25% high, n=188), based on *SLC7A2* expression, the most discriminant gene (online supplementary figure S1A). As observed in the expression heatmap (figure 1A), *USF1* and *TP53* gene expression levels are correlated with the GC patients overall survival. Low mRNA levels of both *USF1* and *TP53* are associated with poor 3-year survival (figure 1B and online supplementary figure S1B). Moreover, for every patient, the mRNA expression levels of *USF1* and p53 are correlated (online supplementary figure S1C) and consequently impact their transcriptional function leading to a significant downregulation of pathways, notably p53-signalling, DNA repair (BER, NER) and cell cycle regulation, in patients with low versus high survival (online supplementary figure S1D). In order to identify the p53 and *USF1*-target genes significantly enriched in the two groups (low vs high survival), we performed Gene Set Enrichment Analysis (<http://software.broadinstitute.org/cancer/software/gsea>) in GC, TCGA dataset (STAD) (online supplementary figure S1E,F). The median expression of

the top-genes enriched in the low and high survival groups (online supplementary figure S2), showed a specific survival rate-dependent expression on both *USF1*-target and p53-target genes (figure 1C). Interestingly, the analysis of another data set from Hippo and colleagues³⁴ (GSE2685), confirmed the decrease of most of *USF1* and p53-regulated genes expression in GC patients, in tumorous versus normal tissues (figure 1D). In parallel, we analysed *USF1* gene expression in gastric biopsies from GC patients. In 50% of these patients, *USF1* expression was lower in the tumorous versus adjacent non-tumoural tissue (fold-change <1; 17/34 patients; p<0.0001) (figure 1E), and 88% (15/17) of patients with low *USF1* expression were *Hp*-positive (online supplementary figure S1G). These data suggest that *Hp*-associated decrease of *USF1* gene expression may define a subgroup of more aggressive gastric tumours. The consequences of *Hp* infection on both *USF1* and p53 target-genes expression were also analysed in gastric cells using expression data from Koeppl and colleagues¹⁶ (GSE55699) and Hong and colleagues (E-GEOD-74577). A significant decrease of *USF1* and *TP53* mRNA levels and target genes, mainly correlated with low survival was observed (figure 1F). These features are also confirmed in *Hp*-infected mice using both expression data from Galamb and colleagues³⁵ (GSE5081) (online supplementary figure S3A) and our previous study³⁶ (E-MEXP-1135) (online supplementary figure S3B).

Absence of *USF1* exacerbates the severity of *Hp*-induced gastric lesions

To determine the consequences of the absence of *USF1* in *Hp*-associated gastric pathogenesis, we infected *Usf1*-KO mice (*Usf1*^{-/-})³⁷ and the parental mice (*Usf1*^{+/+}) with *Hp*SS1 strain which colonises the mouse stomach.³⁸ At each time-point (9/12 months), the infection status was monitored (online supplementary figure S3C) and histological analysis performed (figure 2A,B). Nine-months postinfection (pi), both *Usf1*^{-/-} and *Usf1*^{+/+} mice developed gastric lesions, consisting in infiltration of inflammatory cells, mainly mononucleated cells, in the mucosa and submucosa (figure 2A). A semiquantitative analysis showed an exacerbation of metaplasia and dysplasia in *Usf1*^{-/-} mice compared with *Usf1*^{+/+} (figure 2B). After 9 months, only *Hp*-infected *Usf1*^{-/-} mice showed metaplasia and dysplasia that were absent in *Usf1*^{+/+} infected mice. An important loss of parietal cells favouring hypochlorhydria and atypia was also observed in *Usf1*^{-/-} infected mice. In *Hp*-infected *Usf1*^{+/+} mice, these atypia and dysplasia appeared only after 12 months. At 12 months pi, the gastric inflammation was significantly more severe in *Hp*-infected *Usf1*^{-/-} mice, with score-grading of 2.5 for intestinal metaplasia and parietal cell loss, compared with 1 in *Usf1*^{+/+} mice. In addition, immunofluorescence (IF) analysis of gastric tissue sections shows that in the absence of *USF1* (*Usf1*^{-/-} mice), *Hp* infection strongly promotes p53 loss (figure 2C). This leads to a down regulation of its target genes (*GADD45*, *CDKN1A*, *PCNA*, *RAB31*) (online supplementary figure S3D), in agreement with previous mice data^{35,36} (online supplementary figure S3A,B). Together, these results underscored for the first time a role for *USF1* in gastric carcinogenesis.

Hp impairs DNA repair functions by downregulating *USF1* and p53

Since *USF1* and p53 cooperate to maintain genetic stability, we investigated whether *Hp* impacts *USF1*/p53 functioning. We first showed that at 2 and 24 hours after infection of MKN45 gastric epithelial cells, the expression of *USF1* and *TP53* genes was significantly diminished by the oncogenic strain *Hp*7.13³⁹ (figure 3A,C,E), with a significant and concomitant decrease of




Figure 1 Correlation of p53 and USF1 loss with gastric carcinogenesis and *Hp* infection. (A) Expression heatmap depicting mRNA expression of genes distinguishing most significantly GC patients according to their overall survival. Expression data for (low survival: 665 days or high survival: 1095 days) were obtained from TCGA (STAD, n=188) (see online supplementary figure S1A). (B) Survival curve for GC patients according to *USF1* and *TP53* mRNA levels (low: green, medium: blue or high: red). (C) Expression heatmap depicting median mRNA expression of p53 target genes (Fisher_direct_p53_targets_meta_analysis, GSEA) and putative USF1 target genes (genes having at least one occurrence of transcription factor binding site V\$USF_01 (v7.4 TRANSFAC) in the regions spanning up to 4Kb around their transcription starting sites, gene set enrichment analysis (GSEA),) significantly enriched in both low and high survival GC patients (top 50 genes, see online supplementary figure S1E,F). (D) Expression heatmap depicting p53 and USF1-target genes expression (p53-targets: orange and pink; USF1-targets: blue and green; common: black), previously correlated with low (pink and green) or high survival (orange and blue) using data from Hippo and colleagues³⁴ comparing non-cancerous and cancerous tissues. (E) Relative *USF1* gene expression in gastric biopsies from GC patients (n=34) measured by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) (tumorous vs adjacent tissue); bar: median value. Mann-Whitney test (low (<1) vs high (>1) expression; ****p<0.0001). (F) Log-fold enrichment of p53-target and USF1-target genes expression in *Hp*-infected gastric cells. Data from GSE55699 (Koepfel and colleagues)¹⁶ and E-GEOD-74577 (Hong and colleagues).

their protein levels at 24 hours pi (figure 3B and D). This resulted in the diminution of the expression of USF1 and p53 DNA repair target genes: respectively *CSA*, *HR23A* and *GADD45A* (figure 3F). Similar results were obtained with cells treated with *Hp*7.13 total extracts (50 and 100 µg/mL) (online supplementary figure S4A-E), concomitantly with an increase in DNA damage

hallmark (phosphorylated-histone H2AX, γH2AX) (online supplementary figure S4F). The infection of MKN45 cells with *Hp*SS1 also, inhibited USF1 and p53 levels (online supplementary figure S5). These data, suggest that *Hp*-mediated decrease of USF1 and p53 impacts the DNA repair ability of infected cells and consequently affect their genetic stability.




Figure 2 Loss of USF1 exacerbates gastric tumorigenesis associated to *Hp* infection. *Usf1*^{-/-} and *Usf1*^{+/+} mice were oro-gastrically infected with *HpSS1* for 9 and 12 months as described in online supplementary methods. (A) Representative gastric histological changes on H&E stained tissue section, in *Usf1*^{-/-} (d, e, f, j, k, l) and *Usf1*^{+/+} (a, b, c, g, h, i) mice, *Hp*-infected (b, c, e, f, h, i, j, k, l) and non-infected (a, d, g, j), after 9 months (a–f) and 12 months (g–l). As early as 9 months, cysts and atypia are observed in *Usf1*^{-/-}-infected mice (arrows). Dysplasia is only detected in *Usf1*^{-/-} infected mice at 9 months pi (arrows). (B) Semiquantitative evaluation of gastric lesions in *Hp*-infected *Usf1*^{-/-} and *Usf1*^{+/+} mice (see online supplementary information). Mann-Whitney test, infected versus non-infected (**p*<0.05). (C) p53 (green) and nuclei (Hoechst, blue) on gastric tissue sections from *Hp*-infected *Usf1*^{-/-} and *Usf1*^{+/+} mice at 12 months pi, showing a depletion of p53 in *Hp*-infected *Usf1*^{-/-} mice. Scale bar 100 μ m.

Hp leads to USF1 foci accumulation in the cytoplasm and membrane-surrounding regions of gastric cells

Hp has previously been reported to promote the cytoplasmic p53 proteasomal degradation.^{22–23} USF1 was shown to interact with p53 leading to p53 nuclear stabilisation in response to genotoxic stress.³³ Using IF, we observed that, at 2-hour pi, p53 nuclear staining was significantly lower in *Hp*-infected cells than

in non-infected, as also USF1 nuclear staining (figure 4A,B). More importantly, we detected cytoplasmic USF1 foci-like structures, mainly in the membrane-surrounding area of *Hp*-infected cells at 2 and 24 hours (figure 4A,C; yellow arrows). Quantification of these foci revealed a marked increase with infection time (figure 4C), being present in 80% of *Hp*-infected cells at 24 hours pi. Importantly, a cytoplasmic accumulation




Figure 3 *Hp* impairs host DNA repair function by downregulating USF1 and p53. MKN45 cells were infected with *Hp*7.13 (MOI 100:1) for 2 and 24 hours. Control cells were not infected. (A) *USF1* (B) Western blot analysis of USF1 (C) *TP53* (D) p53 and GAPDH (E) paired *USF1-TP53* (F) *CSA*, *HR23A* and *GADD45A* mRNA level quantified by quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR). Results are relative to the *18S*rRNA. Mean±SD, n=3. (B) WB analysis of (B) USF1 (E) p53 and GAPDH (loading control) in protein extracts from infected and non-infected cells. The histogram below corresponds to immunoblot quantification. Error bars: SD, n=3. Student's t-test, infected versus non-infected (*p<0.05; **p<0.01; ***p<0.0001). *Hp*, *helicobacter pylori*.

of USF1 was also observed in *Hp*-infected INS-GAS mice after 6/12 months in the presence of gastric intraepithelial neoplasia (online supplementary figure S6A,B), with a p53 decrease as reported at 12 months pi (online supplementary figure S6C). Together these results indicate that *Hp* relocates USF1 outside of the nucleus, and promotes USF1 cytoplasmic/membrane accumulation, concomitantly to p53 degradation.

To strengthen this point, we used the well-known DNA-damaging compound, camptothecin (CPT), amplifying the USF1 and p53 genotoxic stress response, as previously reported.³³ Briefly, cells were exposed to CPT (50 nM) and infected by *Hp* or not for 2 and 24 hours. As anticipated, CPT alone induced an immediate DNA-damage response, showed by γH2AX staining (online supplementary figure S7), promoting a strong p53




Figure 4 *Hp* leads to USF1 foci in the vicinity of cell membranes. (A) Immunofluorescence analysis of USF1 and p53 levels and localisation in MKN45 cells infected as in figure 3. p53 immunostaining (red), USF1 (green) and nuclei (Hoechst, blue). Phalloidin actin staining (grey) indicates the cells shape. Scale bar 5 μm. (B) Quantification of USF1 and p53 nuclear intensity (n=150–220 cells/condition). Mann-Whitney test, infected versus non-infected (*p<0.05; ****p<0.0001). (C) Maximum intensity projection of representative *Hp*-infected and non-infected cells at 24 hours. USF1 staining (green) shows foci (yellow arrows) in the cytoplasm and vicinity of cell membranes in infected-cells (left part). Quantification of USF1 spots number per cell according to defined spot criteria as indicated in material and methods (right panel) (n=150–220 cells/condition). Experiments in triplicate with 5–7 microscopic fields analysed. Mann-Whitney test, infected versus non-infected (*p<0.05; ****p<0.0001). *Hp*, *Helicobacter pylori*.

nuclear accumulation 24 hours post-CPT treatment (figure 5A). This p53 increase was significantly reduced in infected cells, as shown by IF quantification (figure 5B). In parallel, while the impact on USF1 expression was mild (figure 5A,B), an important cytoplasmic/membrane accumulation of USF1 foci was observed in CPT-treated cells only in the presence of *Hp*, as confirmed by spots quantification (figure 5A,C). Comparable results were obtained when *Hp*-infection was combined with different genotoxic stress compounds (MMS, H₂O₂) (online supplementary figure S8 and S9). Together this strongly supports the important and specific role of *Hp* on USF1 and p53 biological function.

Hp impairs the formation of USF1/p53 complexes

To investigate the mechanism by which *Hp* impairs USF1 and p53 function, we followed the formation of USF1/p53 complexes in response to CPT-induced genotoxic stress and infection using proximity ligation assay (PLA).⁴⁰ According to its genotoxic activity, CPT alone induces nuclear USF1/p53 complexes, with a marked increase after 24 hours. In CPT-treated/*Hp*-infected

cells, the formation of these complexes is abrogated. Thus, CPT exacerbated *Hp*-mediated effects with a stronger inhibition of the formation of USF1/p53 complexes, compared with *Hp* infection alone (figure 6A,B). Together, this shows that minute nuclear amounts of USF1 in infected cells are associated with the absence of USF1/p53 nuclear complexes, impairing p53 stabilisation in agreement with its *Hp*-mediated degradation.^{22 23}

Hp infection sensitises gastric cells to genotoxic stress

We next investigated whether *Hp* infection could sensitise cells to DNA-damage. To address this important clinical question, cells were first infected with *Hp*7.13 for 24 hours, washed several times prior to their treatment with CPT (50 nM) for 24 hours (figure 7A). Here also, *Hp*-infected cells displayed accumulation of USF1 foci mainly at their periphery with low p53 staining, while CPT-treatment alone, promotes USF1 and p53 nuclear increase (figure 7B). Sensitising cells with *Hp* 24 hours prior to CPT-treatment still leads to an important accumulation of USF1 foci in the cytoplasm and surrounding-membrane cell area




Figure 5 USF1 foci are specifically induced by *Hp* infection. (A) Immunofluorescence analysis of USF1 and p53 levels and localisation, in MKN45 cells treated or not with CPT (50 nm) and infected with *Hp* 7.13 for 2 and 24 hours. p53 (red), USF1 (green), nuclei (Hoechst, blue) and phalloidin actin staining (grey). The delocalisation and accumulation of USF1 are specifically observed in the cytoplasm and membrane surrounding area of *Hp*-infected/CPT-treated cells. Scale bar 5 μ m. (B) Quantification of USF1 and p53 nuclear intensity (n=150–220 cells/condition). (C) Quantification of USF1 spots number/cell as in figure 4. USF1 foci are only observed in the presence of *Hp* (n=150–220 cells/condition). Mann-Whitney test: treated or treated/infected versus control (**p<0.01; ***p<0.001; ****p<0.0001). Experiments in triplicate with 5–7 fields analysed. CPT, camptothecin; *Hp*, *Helicobacter pylori*.

(figure 7B). Importantly, we noticed the presence of p53-positive micronuclei-like structures (figure 7B, yellow arrows), a signature of elevated genotoxic stress⁴¹ known to accumulate p53,⁴² as under our conditions. Same results were observed with MMS and H₂O₂-treated cells (1mM) (online supplementary figure S10). Thus, *Hp*-induced USF1 cytoplasmic/peripheral accumulation is maintained postinfection, rendering the cells more susceptible to DNA-damaging agents.

DISCUSSION

The impairment of p53 function plays a key role in the promotion of carcinogenesis. We previously showed that UV-induced p53

stabilisation and subsequent transient cell-cycle arrest requires USF1.³³ Up to now, no direct in vivo evidence linking USF1 to cancer was provided, although molecular data were in favour of such a role.^{30 43 44} Studies associated *USF1* polymorphisms with increased risk of cancer.^{45–47} Here, we demonstrate for the first time that loss of USF1 promotes *Hp*-induced carcinogenesis. First, the in vivo absence of USF1 in *Usf1*^{-/-} mice, leads to p53 depletion and accelerates the development and triggers the severity of *Hp*-induced gastric lesions. More importantly, these mice recapitulate the sequential gastric preneoplastic cascade described in human pathology.³ *Usf1*^{-/-} mice constitute thus an interesting model to study *Hp*-induced gastric carcinogenesis.




Figure 6 *Hp* inhibits the USF1/p53 complexes in response to a chemical genotoxic stress. (A) Duolink PLA analysis of USF1/p53 complexes (pink foci), in *Hp*-infected cells either CPT-treated (50 nM) or not as described in methods. nuclei (Hoechst, blue). Experiments in duplicate (5–7 fields analysed). Scale bar: 10 μ m for each time-point; right panels zoom: fields delimited in red, scale bar 5 μ m. (B) Quantification of USF1/p53 nuclear interaction (5–7 fields analysed). Student's t-test, CPT-treated and/or infected versus control (* p <0.05; ** p <0.01; *** p <0.001). CPT, camptothecin; *Hp*, *Helicobacter pylori*; PLA, proximity ligation assay.

Second, in human GC samples, *USF1* and *TP53* gene expression is associated with patient prognosis (TCGA analysis), as low transcriptional levels correlate with poor 3 years survival. Moreover, *USF1* and *TP53* expression levels directly impact their target genes such as those related to DNA repair, cell cycle regulation and p53 signalling pathways. Furthermore, low *USF1* gene expression in GC patients is mainly associated with *Hp* status. Thus, *Hp*-positive gastric tumours with low *USF1* and *TP53* levels may identify a subgroup of patients with poor prognosis. Together these data demonstrate that USF1 has tumour suppressive functions and that its low level should be considered as a potential marker of cancer susceptibility.

We also show that *Hp* infection delocalises the nuclear factor USF1 at the periphery of cells into foci that resemble aggregates. This occurs concomitantly with a diminution of its nuclear amount, as schematised in figure 8A. This phenotype is only observed in *Hp*-infected cells and not after exposure to DNA damaging agents. The unexpected cellular localisation of USF1 may impair its transcriptional regulatory function, reducing the expression of its NER target genes *CSA* and *HR23A* in infected cells. It also controls its biological function, impairing nuclear USF1/p53 complex formation. Indeed, *Hp*-mediated USF1 depletion diminishes the stabilisation of p53 that is known to




Figure 7 *Hp* infection makes more susceptible gastric cells to a genotoxic stress. (A) Experimental schedule. MKN45 cells were first infected with *Hp* 7.13 or not, as in figure 3. After 24 hours, cells were washed three times and either treated or not with CPT (50 nM) for 24 hours. (B) Immunofluorescence analysis of USF1 (green) and p53 (red). nuclei (Hoechst, blue) and phalloidin actin staining (grey). Experiments in duplicate (5–7 fields analysed per condition). Scale bar 5 μ m. CPT, camptothecin; *Hp*, *Helicobacter pylori*.

contribute to genetic instability and oncogenic properties of the infection.

USF1 as part of the b-HLH-LZ transcription factor family is well known for its nuclear function.²⁹ The *Hp*-mediated delocalisation of USF1 outside the nucleus was unexpected. The underlying mechanism and the cellular structure involved remain to be clarified. It may well be that *Hp*-infection induces USF1 post-translational modifications modulating its nuclear-cytoplasmic trafficking, that results in its cytoplasmic/membrane accumulation. This could represent an *Hp* strategy to prevent USF1 transcriptional function, impairing its tumour suppressive activity and DNA repair functions. Alternatively, USF1 foci could correspond to protein aggregation due to infection-induced misfolding, as recently reported the formation of aggresomes by Twist1, another b-HLH-LZ transcription factor.⁴⁸

In response to a genotoxic stress, USF1 and p53 interact promoting p53 stabilisation and blocking its interaction with the E3-ubiquitin ligase HDM2, thereby abrogating subsequent p53 degradation.³³ We show that nuclear depletion of USF1 parallels the p53 decrease in *Hp*-infected cells. Under this condition, we speculate that the nuclear level of USF1 is too low to ensure p53 stabilisation, limiting the formation of USF1/p53 complexes. Importantly, infection of cells by *Hp* prior to CPT (MMS or H₂O₂)-treatment maintains the cytoplasmic/membrane delocalisation of USF1, indicating that once initiated this process is sustained even in the absence of a new *Hp* challenge. *Hp*-induced accumulation of USF1 outside the nucleus could thus constitute a 'point of no return,' after which USF1 is no more available to undertake its nuclear functions. This suggests that *Hp*-infection may weaken DNA repair ability of cells exposed to genotoxic stress. As illustrated in figure 8B, *Hp* can persist all lifelong, promoting DNA damage, which thus results from the combined effects of the infection and exposure to genotoxic environmental factors, increasing the risk of GC.




Figure 8 Schematic representation of the data. (A) Gastric epithelial cells infected with *Hp* show lower nuclear level of USF1 and p53 and the formation of USF1 foci mainly at the periphery of cells close to membranes. *Hp* infection inhibits USF1 and CPT-induced USF1/p53 complexes in the nuclei. These data support that, in response to a genotoxic stress, the nuclear localisation of USF1 is important to maintain p53 in the nucleus to carry out its function. (B) Exacerbation of gastric carcinogenesis due to synergistic effects of *Hp* and environmental DNA damaging factors in chronically infected individuals. According to our data, the progressive nuclear decrease of USF1 and p53 in *Hp*-positive subjects should lead to further accumulation of DNA damage all lifelong. This supports that *Hp* increases the sensitivity to DNA damaging effects of genotoxic environmental factors, thus promoting the risk of GC. CPT, camptothecin; GC, gastric cancer; *Hp*, *Helicobacter pylori*.

In conclusion, this study demonstrated that USF1 is a new central regulator of DNA damage and repair in response to *Hp* infection. The absence of USF1 results in the promotion of gastric carcinogenesis as demonstrated in vivo with the *Usf1*^{-/-} mice, which constitute a new powerful tool to deepen our understanding of the molecular cascade from preneoplasia to GC development. Our findings are also of clinical relevance and pave the way to propose the USF1 level as a potential biomarker for GC.

METHODS

Cells culture and bacteria growth conditions, mice infection and histology, analysis of genes expression, proteins and imaging procedures and data banks used in in silico study are reported in online supplementary information.

Bacteria and cells

Human gastric epithelial cells, MKN45 (received from C. Reis's laboratory, Porto, Portugal), were used in this study and infected with *Hp* strains 7.13³⁹ and SS1.³⁸

Analysis of protein complexes by PLA

The USF1/p53 complexes were visualised by Duolink PLA,⁴⁰ as reported in online supplementary information. Imaging analysis was carried out using an inverted widefield microscope Axio Observer Z1 equipped with Apotome grid (Carl Zeiss, Germany).

Human gastric biopsies

All patients were adults, informed and signed a consent letter.

Gastric biopsies (tumorous and adjacent tissue) were from GC patients who attended the Instituto Mexicano del Seguro Social, Medical Center SXXI in Mexico (n=28) and the Florence University Hospital (n=6). For each patient, diagnosis was based on endoscopic examination and histopathological analysis.

Hp infection in mice

Mice experiments were carried out according to the European Directives (2010/63/UE).

Usf1^{-/-37} and *Usf1*^{+/+} mice (C57BL/6j 129SV) were from S. Vaulont (Institut Cochin, Paris, France) and INS-GAS mice^{49 50} from TC Wang (Columbia University College, New York, USA).

Statistical analysis

Statistical analysis was performed using the Student's t-test or Mann-Whitney test, after being assessed for normality of samples distribution. Results were considered significant if p<0.05. Kaplan-Meier survival analysis assumption was performed on the TCGA data set (<https://cancergenome.nih.gov>).

Author affiliations

- ¹Unit of Helicobacter Pathogenesis, Department of Microbiology, CNRS ERL6002, Institut Pasteur, Paris, France
- ²INSERM U1016, CNRS UMR 8104, Institut Cochin, Paris, France
- ³Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- ⁴Institut de Génétique et Développement, Université de Rennes 1, Rennes, France
- ⁵UtechS PBI-C2RT, Institut Pasteur, Paris, France
- ⁶Pathogenesis of Systemic Infection, Institut Fédératif de Recherche Necker-Enfants Malades, Paris, France
- ⁷Unit of Experimental Neuropathology, Department of Global Health, Institut Pasteur, Paris, France
- ⁸AgroSup, Laboratoire PAM UMR A 02.102, Université de Bourgogne, Dijon, France
- ⁹Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, UMAE Pediatría, Instituto Mexicano del Seguro Social (IMSS), México city, Mexico
- ¹⁰Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
- ¹¹Institut Mutualiste Montsouris, Paris, France
- ¹²CHU, Department of Molecular Genetics and Genomics, Université de Rennes 1, Rennes, France

Acknowledgements We thank Sophie Vaulont (Institut Cochin, Paris, France) for *Usf1*^{-/-} mice, Timothy C Wang (Columbia University, NY, USA) for providing us couples of INS-GAS mice and Joana Gomes and Celso Reis (IBS-IPATIMUP, Porto, Portugal) for MKN45 cells. We also thank Laurence Bernard-Touami and the Animal Housing ARCHE (UMS Biosit, <https://biosit.univ-rennes1.fr>, University of Rennes, France), and David Hardy and Magalie Tichit (Unit of Experimental Neuropathology, Institut Pasteur, Paris, France) for her technical help on the histology part and the UtechS Photonic Bioluminescence (Imagopole), C2RT, Institut Pasteur, supported by the French National Research Agency (France Bioluminescence; ANR-10-INSB-04; Investments for the Future), both as a part of the FranceBioluminescence infrastructure.

Contributors Study concept and design: LC, SC, M-DG, ET; experiments and acquisition of data: LC, SC, VM, KLL, JF, JZ, GJ, NM, DDSB, LF, ET; analysis of data and statistics: LC, SC, AD, M-DG, ET; patient data and samples collection: JT, MC, MMD; drafting of the manuscript: SC, M-DG, ET; critical revision of the manuscript: JT, MMD, HDR; reading and approval of the manuscript: all authors; study supervision and funding: MD-G, ET.

Funding This work was supported by funding from the Odyssey Reinsurance Company to ET, the West committee of the Ligue Nationale Contre le Cancer (LNCC) and the UMS Biosit to MDG. JT received financial support from Fondo de Investigación en Salud, IMSS, Mexico (FIS/IMSS/PROT/PRI0/13/027). The LNCC provided a doctoral fellowship to LC and the Odyssey Reinsurance company financed JF postdoctoral fellowship. KLL is a doctoral fellow from the University Paris Diderot, Ecole Doctorale Bio Sorbonne Paris Cité (BioSPC).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study was approved by the Local Ethical Committees from the National Council for Research on Health, Instituto Mexicano del Seguro Social, Mexico and Florence University Hospital, Italy. The project was

approved by the Comité d'Éthique en Expérimentation Animale (CETEA), Institut Pasteur (Ref 00317.02) and the Federative Structure of Research, Rennes (Ref APAFIS#905–2015060515515795 v4).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Eliette Touati <http://orcid.org/0000-0002-3450-1773>

REFERENCES

- Peek RM, Blaser MJ. *Helicobacter pylori* and gastrointestinal tract adenocarcinomas. *Nat Rev Cancer* 2002;2:28–37.
- Kim SS, Ruiz VE, Carroll JD, et al. *Helicobacter pylori* in the pathogenesis of gastric cancer and gastric lymphoma. *Cancer Lett* 2011;305:228–38.
- Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Res* 1992;52:6735–40.
- Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. *Lancet Glob Health* 2016;4:e609–16.
- Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (maps II): European Society of gastrointestinal endoscopy (ESGE), European Helicobacter and microbiota Study Group (EHMSG), European Society of pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. *Endoscopy* 2019;51:365–88.
- Malfertheiner P, Mégraud F, O'Morain CA, et al. Management of *Helicobacter pylori* infection—the Maastricht V/Florence Consensus Report. *Gut* 2017;66:6–30.
- Rugge M, Genta RM, Di Mario F, et al. Gastric cancer as preventable disease. *Clin Gastroenterol Hepatol* 2017;15:1833–43.
- Mommersteeg MC, Yu J, Peppelenbosch MP, et al. Genetic host factors in *Helicobacter pylori*-induced carcinogenesis: Emerging new paradigms. *Bioch Biophys Acta Rev Cancer* 1869;2018:42–52.
- Hardbower DM, de Sablet T, Chaturvedi R, et al. Chronic inflammation and oxidative stress: the smoking gun for *Helicobacter pylori*-induced gastric cancer? *Gut Microbes* 2013;4:475–81.
- Touati E, Michel V, Thiberge J-M, et al. Chronic *Helicobacter pylori* infections induce gastric mutations in mice. *Gastroenterology* 2003;124:1408–19.
- Touati E, Michel V, Thiberge J-M, et al. Deficiency in OGG1 protects against inflammation and mutagenic effects associated with *H. pylori* infection in mouse. *Helicobacter* 2006;11:494–505.
- Machado AMD, Figueiredo C, Touati E, et al. *Helicobacter pylori* infection induces genetic instability of nuclear and mitochondrial DNA in gastric cells. *Clin Cancer Res* 2009;15:2995–3002.
- Toller IM, Neelsen KJ, Steger M, et al. Carcinogenic bacterial pathogen *Helicobacter pylori* triggers DNA double-strand breaks and a DNA damage response in its host cells. *Proc Natl Acad Sci U S A* 2011;108:14944–9.
- Hartung ML, Gruber DC, Koch KN, et al. *H. pylori*-Induced DNA Strand Breaks Are Introduced by Nucleotide Excision Repair Endonucleases and Promote NF- κ B Target Gene Expression. *Cell Rep* 2015;13:70–9.
- Kim JJ, Tao H, Carloni E, et al. *Helicobacter pylori* impairs DNA mismatch repair in gastric epithelial cells. *Gastroenterology* 2002;123:542–53.
- Koepfel M, Garcia-Alcalde F, Glowinski F, et al. *Helicobacter pylori* infection causes characteristic DNA damage patterns in human cells. *Cell Rep* 2015;11:1703–13.
- Matsumoto Y, Marusawa H, Kinoshita K, et al. *Helicobacter pylori* infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. *Nat Med* 2007;13:470–6.
- Wada Y, Takemura K, Tummala P, et al. *Helicobacter pylori* induces somatic mutations in TP53 via overexpression of CHAC1 in infected gastric epithelial cells. *FEBS Open Bio* 2018;8:671–9.
- Meek DW. Tumour suppression by p53: a role for the DNA damage response? *Nat Rev Cancer* 2009;9:714–23.
- Eischen CM. Genome stability requires p53. *Cold Spring Harb Perspect Med* 2016;6:a026096.
- Chumduri C, Gurumurthy RK, Zietlow R, et al. Subversion of host genome integrity by bacterial pathogens. *Nat Rev Mol Cell Biol* 2016;17:659–73.
- Wei J, Nagy TA, Vilgelm A, et al. Regulation of p53 tumor suppressor by *Helicobacter pylori* in gastric epithelial cells. *Gastroenterology* 2010;139:1333–43.
- Buti L, Spooner E, Van der Veen AG, et al. *Helicobacter pylori* cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. *Proc Natl Acad Sci U S A* 2011;108:9238–43.
- Coombs N, Sompallae R, Olbermann P, et al. *Helicobacter pylori* affects the cellular deubiquitinase USP7 and ubiquitin-regulated components TRAF6 and the tumour suppressor p53. *Int J Med Microbiol* 2011;301:213–24.
- Maekita Tet al. High levels of aberrant DNA methylation in *Helicobacter pylori*-infected gastric mucosae and its possible association with gastric cancer risk. *Clinical Cancer Research* 2006;12:989–95.
- Touati E. When bacteria become mutagenic and carcinogenic: lessons from *H. pylori*. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis* 2010;703:66–70.
- Servetas SL, Bridge DR, Merrell DS. Molecular mechanisms of gastric cancer initiation and progression by *Helicobacter pylori*. *Curr Opin Infect Dis* 2016;29:304–10.
- Bussière FI, Michel V, Mémet S, et al. *H. pylori*-induced promoter hypermethylation downregulates USF1 and USF2 transcription factor gene expression. *Cell Microbiol* 2010;12:1124–33.
- Corre S, Galibert M-D. Upstream stimulating factors: highly versatile stress-responsive transcription factors. *Pigment Cell Res* 2005;18:337–48.
- Ismail PM, Lu T, Sawadogo M. Loss of USF transcriptional activity in breast cancer cell lines. *Oncogene* 1999;18:582–91.
- Chen N, Szentirmay MN, Pawar SA, et al. Tumor-suppression function of transcription factor USF2 in prostate carcinogenesis. *Oncogene* 2006;25:579–87.
- Baron Y, Corre S, Mouchet N, et al. Usf-1 is critical for maintaining genome integrity in response to UV-induced DNA photolesions. *PLoS Genet* 2012;8:e1002470.
- Bouafia A, Corre S, Gilot D, et al. P53 requires the stress sensor USF1 to direct appropriate cell fate decision. *PLoS Genet* 2014;10:e1004309.
- Hippo Y, Taniguchi H, Tsutsumi S, et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. *Cancer Res* 2002;62:233–40.
- Galamb O, Györfy B, Sipos F, et al. *Helicobacter pylori* and antrum erosion-specific gene expression patterns: the discriminative role of CXCL13 and VCAM1 transcripts. *Helicobacter* 2008;13:112–26.
- Vivas JR, Regnault B, Michel V, et al. Interferon gamma-signature transcript profiling and IL-23 upregulation in response to *Helicobacter pylori* infection. *Int J Immun Pharm* 2008;21:515–26.
- Vallet VS, Casado M, Henrion AA, et al. Differential roles of upstream stimulatory factors 1 and 2 in the transcriptional response of liver genes to glucose. *J Biol Chem* 1998;273:20175–9.
- Lee A, O'Rourke J, De Ungria MC, et al. A standardized mouse model of *Helicobacter pylori* infection: introducing the Sydney strain. *Gastroenterology* 1997;112:1386–97.
- Franco AT, Israel DA, Washington MK, et al. Activation of β -catenin by carcinogenic *Helicobacter pylori*. *Proc Natl Acad Sci U S A* 2005;102:10646–51.
- Söderberg O, Gullberg M, Jarvius M, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. *Nat Methods* 2006;3:995–1000.
- Luzhna L, Kathiria P, Kovalchuk O. Micronuclei in genotoxicity assessment: from genetics to epigenetics and beyond. *Front Genet* 2013;4:131.
- Granetto C, Ottaggio L, Abbondandolo A, et al. P53 accumulates in micronuclei after treatment with a DNA breaking chemical, methylnitrosourea, and with the spindle poison, vinblastine. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis* 1996;352:61–4.
- Horbach T, GÄrtz C, Kietzmann T, et al. Protein kinases as switches for the function of upstream stimulatory factors: implications for tissue injury and cancer. *Front Pharmacol* 2015;6:3.
- Chang JT-C, Yang H-T, Wang T-CV, et al. Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells. *Mol Carcinog* 2005;44:183–92.
- Zhao X, Wang T, Liu B, et al. Significant association between upstream transcription factor 1 rs2516839 polymorphism and hepatocellular carcinoma risk: a case-control study. *Tumor Biology* 2015;36:2551–8.
- Zhou X, Zhu H-qiang, Ma C-qun, et al. Two polymorphisms of USF1 gene (–202G>A and –844C>T) may be associated with hepatocellular carcinoma susceptibility based on a case-control study in Chinese Han population. *Med Oncol* 2014;31.
- Yuan Q, Bu Q, Li G, et al. Association between single nucleotide polymorphisms of upstream transcription factor 1 (USF1) and susceptibility to papillary thyroid cancer. *Clin Endocrinol* 2016;84:564–70.
- Govindarajulu G, Selvam M, Palchamy E, et al. N-Terminal truncations of human bHLH transcription factor Twist1 leads to the formation of aggregates. *Mol Cell Biochem* 2018;439:75–85.
- Fox J, Rogers A, Ihrig M, et al. *Helicobacter pylori* associated gastric cancer in INS-GAS mice is gender specific. *Can Res* 2003;63:942–50.
- Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and *Helicobacter* infection in a mouse model of gastric cancer. *Gastroenterology* 2000;118:36–47.